# A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Source: https://onco.cc/trials/nct07450859/  
OnCo record `nct07450859` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of nuzefatide pevedotin (BT5528) in pancreatic ductal adenocarcinoma, run by BicycleTx Limited, now recruiting.

## Summary

A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) is a phase 2 interventional study registered as NCT07450859 by BicycleTx Limited, with 39 participants planned, started 2026-03-05 and due to reach its primary completion in 2029-03. Interventions recorded: nuzefatide pevedotin (BT5528).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07450859
- Phase: 2
- Setting: A Phase 2 Study of BT5528 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
- Sponsor: BicycleTx Limited
- Enrolled: 39

## Sources

- ClinicalTrials.gov NCT07450859: https://clinicaltrials.gov/study/NCT07450859

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)

---
JSON: https://onco.cc/api/v1/entities/nct07450859.json